COVID-19 Research Viewer Gadget and Other Pandemic-Related Measures Remove Barriers to Relevant and Most Recent Scientific Literature
ENCINO, Calif., April 14, 2020 — Research Solutions, Inc. (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D-driven organizations, and its wholly owned subsidiary Reprints Desk, today announced a series of new COVID-19 initiatives, including the launch of the COVID-19 Research Viewer Gadget, the latest addition to the Article Galaxy platform. The Company’s new initiatives are aimed at simplifying scientific literature discovery and acquisition during the COVID-19 crisis. For a summary of these ongoing COVID-19 initiatives, please visit info.reprintsdesk.com/coronavirus.
“Research Solutions is committed to helping in the struggle against the COVID-19 virus,” said Peter Derycz, CEO and President of Research Solutions. “While we can’t create a magic-bullet cure, we can contribute to the research community’s global efforts through ensuring seamless and efficient access to scientific literature. Reliable research at high velocity is critical – now more than ever.”
COVID-19 Research Viewer Gadget
The COVID-19 Research Viewer Gadget provides an up-to-date listing of COVID-19 scientific literature, across all publishers, most of which have committed to removing paywalls from COVID-19 articles. Built using PubMed as the data source, the Gadget displays thousands of COVID-19 journal articles at a glance and features an interactive map with the current number of confirmed cases and mortality statistics across the globe. Other functions include:
- Most Requested COVID-19 Articles tab: Filters results based on most popular articles
- Most Recent COVID-19 Articles tab: Filters results by most recent publication date
- Publisher Resources tab: Provides a list of COVID-19 portals developed by publishers
Research Solutions is working on further enhancements to the COVID-19 Research Viewer Gadget. The Gadget is available free of charge to customers, regardless of subscription level. In addition, anyone interested in COVID-related research can view the Gadget’s publicly available interactive website at coronarpd.firebaseapp.com.
New Billing Policy for Copyright-Free COVID-19 Articles
“Publishers are incredibly responsive. Most are removing paywalls, in some cases retroactively, on peer-reviewed articles related to the COVID-19 pandemic,” said Derycz. “Since the distribution of metadata for these articles can’t always keep up with these changes, there will likely be cases where our customers order articles that should be free of any copyright charge, but were not initially delivered for free or may have shown a price at the time they were ordered.”
To ensure customers do not pay for any articles for which paywalls have been removed, Research Solutions will run a monthly analysis of its billing data and remove any copyright charges for papers that publishers have made available for free. In cases where a customer believes they were mistakenly charged for COVID-19 articles, Research Solutions offers an open refund policy for COVID-19 articles, promising to reverse the charges for any copyright fees confirmed to have been billed in error.
A fully-virtual company, Research Solutions has been able to operate without interruption during the recent stay-at-home policies that have been implemented around the world. Based on years of experience with the systems, tools, security, processes, and procedures needed to efficiently operate in a virtual environment, the Company is now extending itself as a resource for its customers, partners, and suppliers looking for advice and ideas on how to best optimize their remote operations amidst this challenging situation.
About Research Solutions and Reprints Desk
Research Solutions, Inc. (NASDAQ: RSSS) is a pioneer in providing seamless access to scientific research. Its wholly-owned subsidiary Reprints Desk, Inc., simplifies how organizations and individual researchers discover, acquire, and manage scholarly journal articles, book chapters and other content in scientific, technical, and medical (STM) research. More than 70 percent of the top pharmaceutical companies, prestigious universities, and emerging businesses rely on Article Galaxy, Reprints Desk’s cloud-based SaaS research platform, for simplified and lowest cost access to the latest scientific research and data. Featuring an ecosystem of app-like Gadgets for a personalized research experience, Article Galaxy offers individual as well as enterprise plans, coupled with unparalleled, 24/7 customer support. For more information and details, please visit www.researchsolutions.com and www.reprintsdesk.com
Certain statements in this press release may contain "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in the Company's most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Examples of forward-looking statements in this release include statements regarding simplifying scientific research and discovery during the COVID-19 crisis, further enhancements to the COVID-19 Research Viewer Gadget, and monthly billing analyses. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to the Company's filings with the Securities and Exchange Commission.